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Systems biology uses mathematical models to analyze large datasets and simulate system behavior. It
enables integrative analysis of different types of data and can thereby provide new insight into complex
biological systems. Here will be discussed the challenges of using systems medicine for advancing the
development of personalized and precision medicine to treat metabolic diseases like insulin resistance,
obesity, NAFLD, NASH, and cancer. It will be illustrated how the concept of genome-scale metabolic models
can be used for integrative analysis of big data with the objective of identifying novel biomarkers that are
foundational for personalized and precision medicine.Introduction
Healthcare costs are rapidly increasing in the developing coun-
tries, and in 2011 the total healthcare spending in the United
States accounted for about 18% of its GDP (WHO, 2011), a
63% inflation-adjusted increase since 1997 (Pfuntner et al.,
2011). Despite this, many people are taking drugs that will not
benefit them. In a recent survey of the top ten highest selling
drugs in the USA, it was reported that for each person benefitting
from any of these drugs, between 4 and 25 people are not being
helped (Schork, 2015). The healthcare sector is therefore in need
of transformation, both to reduce costs and to ensure better
treatment of patients. This requires that physicians consider
the large variation between individuals to reach this objective.
Most currently used pharmaceuticals have been developed
based on clinical trials involving large cohorts and are given to
patients on the assumption that everyone will respond similarly.
This is neglecting the fact that there are large genetic and envi-
ronmental differences between individuals, and recently it has
also been found that the gut microbiome has an influence on
drug response, adding further complexity. In order to take these
variations into consideration, there is increasing interest in the
concept of personalized medicine, which is based on stratifica-
tion of patients into different molecularly defined groups and
then using different treatments and/or interventions for each
group (Figure 1A). With accumulating knowledge on the molec-
ular mechanisms for many diseases and the development of
more efficient diagnosis, there is increasing interest in moving
from disease treatment, the current practice, to disease preven-
tion, as this will significantly reduce costs in the healthcare
sector. This, however, requires that identified biomarkers have
truly predictive strength, something that can only be obtained
through dedicated clinical studies, preferentially longitudinal
over long time. Studies that focus on individuals, known as
N-of-1 trials (Figure 1B), are important for this, as these will pro-
vide data on variations within and between individuals and here-
by will enable the identification of which biomarkers that can be
used for solid stratification and for detection of disease onset.
OftenN-of-1 trials engage the patients actively, i.e., they become572 Cell Metabolism 25, March 7, 2017 ª 2017 Elsevier Inc.participatory. The concept of preventive, predictive, personal-
ized, and participatory medicine has been coined P4 medicine
(Hood and Friend, 2011), and this may completely transform
the healthcare sector in the next 10–20 years.
Through N-of-1 trials on a large number of people, it will
become possible to develop more detailed data-driven models
for how different biomarkers, and possible even with different
quantitative levels, are associated with disease development
and thereby enable precision medicine, where the treatment is
tailored to deal with a specific molecular event underlying the
disease. There are already some ongoing N-of-1 studies where
healthy people are beingmonitored in detail over time, one being
the so-called 100K project where the objective is to enroll
100,000 individuals and follow them longitudinally for 20 or
more years (Hood and Price, 2014). This project follows a
9-month pilot study called the Hundred Person Wellness Project
(HPWP), where 100 individuals were intensively monitored and
offered regular feedback and counseling about lifestyle changes,
e.g., suggested dietary changes or altered sleeping habits
(Gibbs, 2014). In the HPWP, all individuals had their genome
sequenced at enrollment. Furthermore, insulin sensitivity, im-
mune cell activity, 100 key proteins, and the gut microbiome
composition were monitored at enrollment and every 3 months.
Finally, pulse and sleeping patterns were monitored continu-
ously using a wrist sensor. This resulted in the generation of a
very large amount of data for each individual, a virtual data cloud
consisting of billions of data points, and the challenge ahead is to
ensure efficient analysis of these data and extract information
that can be used for direct advice on lifestyle and/or treatment
strategies (Hood, 2013). Analysis of this kind of big data is chal-
lenging, as discussed later, but through the integration of the
data with mathematical models or reconstructed biological net-
works, much new biological information can be derived. The use
of computational and mathematical models for studying biolog-
ical systems is referred to as systems biology, and when applied
specifically for studying human diseases as systems medicine
(Hood, 2013). Here I will discuss the challenges of systems
medicine and illustrate how one type of mathematical model,
AB
Figure 1. Principles of Personalized Medicine
(A) Illustration of how analysis of big data obtained from detailed omics analysis of patient cohorts can result in detailed phenotyping and thereby lead to
stratification of patients into different groups. In connection with this, there can be identified a set of biomarkers that can be used for the stratification in the clinic.
These biomarkers are uniquemolecules (or combination of molecules), e.g., metabolites or proteins, that pass a certain level when specific cellular processes are
changed in connection with disease onset or progression.
(B) Illustration of the concept of N-of-1 trials. Each individual in the cohort is followed over time, during which samples are taken at different time points. This
detailed phenotyping over time enables identification of deviations from normal, which may point to disease development. Furthermore, N-of-1 trials will provide
information on variations of biomarkers both within and between individuals, and this will be important for identification of biomarkers that are truly predictive and
can therefore be used for stratification of cohorts not included in the N-of-1 study.
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Perspectivethe so-called genome-scale metabolic model (GEM), can be
used as a scaffold for integrative analysis with the objective to
identify novel prognostic biomarkers that can assist in the
advancement toward personalized and precision medicine.
Challenges for Systems Medicine
Advancing systems medicine faces several challenges: (1) the
challenge of analyzing large datasets, (2) the difficulties in iden-
tifying mechanistic causes for many biomarkers and drug tar-
gets, (3) problems with translation from model systems to the
clinic, and (4) problems with sample heterogeneity.
The detailed analysis underlying systems medicine results in
generation of very large datasets, generally referred to as big
data. Even though they are smaller in size than other types of big
data generated, e.g., in the financial sector, traffic control, and
meteorology, it is challenging to analyze multiple types of omics
data as there is a large variation in data structures and formats.
Thus, a recent analysis demonstrated that with four different
data types, the resources required for data analysis are larger
than the resources for data generation for only four datasets,
and the resource requirement for data analysis increases rapidly
when more datasets are to be analyzed (Palsson and Zengler,
2010). This is because different data types need to be pre-pro-cessedseparatelybefore theycanbeused for integrative analysis.
Another challenge is thatmulti-omicsdata represent varying types
of informationwith very different timescales and different dynamic
ranges. Thus, metabolites change with completely different time
constants than mRNAs and proteins, and the level of metabolites
inacell isdeterminednotonlyby theenzyme levels, but alsoby the
kinetics of the individual enzymes; by post-translational modifica-
tion of enzymes, e.g., protein phosphorylation and acetylation;
andbymetabolite regulation.Furthermore,metabolitescirculating
in thebloodaredeterminednotonlyby themetabolic activityof the
different tissues, but also by the food intake and by the metabolic
activity of the human gut microbiota. Similarly, the plasma prote-
ome isacomplex functionof thephysiological stateof thedifferent
tissues and cell types in the body. It is therefore challenging to
apply plasma metabolomics or proteomics for diagnosis and to
integrate thesedatawithother omicsdata, unlessoneusesa scaf-
fold thatprovidesapriori informationonhowthedifferent variables
are connected.
Metabolism is closely integrated with practically all cellular
processes, and any kind of perturbation in cellular physiology
therefore typically results in an altered metabolic footprint, i.e.,
altered uptake or secretion of metabolites from or to the blood.
Plasma metabolomics data therefore have a huge potential forCell Metabolism 25, March 7, 2017 573
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widely used for monitoring of triacylglycerides and cholesterols
in the blood, but analysis of blood chemistry could probably be
used much more widely for diagnosis. However, it is a major
challenge to link an altered metabolite profile to onset or pro-
gression of a specific disease. To illustrate the complexity, the
Human Metabolome Database (HMDB) includes about 42,000
metabolites (Wishart et al., 2013; www.hmdb.ca). A large num-
ber of these are food metabolites (about 32,500) and drug me-
tabolites (about 2,500), but still about 4,500 metabolites have
been reported in serum (Psychogios et al., 2011; www.hmdb.
ca). With so many metabolites present in human serum, and
the large sensitivity of the levels of many of these toward lifestyle
differences, in particular diet, it is of course challenging to iden-
tify biomarkers associated with specific diseases solely from
human serum metabolome analysis. Only few biomarkers have
therefore been identified from this kind of analysis, exemplified
by the identification of elevated levels of branched-chain amino
acids as amarker for obesity and diabetes (Newgard et al., 2009;
Zhao et al., 2016). Even though transcriptome analysis of
abdominal human fat biopsies, enriched in adipocytes, showed
that elevated levels of branched-chain amino acids in obese
subjects may be caused by reduced respiratory metabolism in
this tissue (Mardinoglu et al., 2014a), there is still lacking amech-
anistic explanation for why these amino acids are such strong
biomarkers for obesity and diabetes. More detailed analysis of
metabolic alterations in different tissues is required for obtaining
a mechanistic explanation for this finding, and this will require
both large datasets, e.g., transcriptome or proteome data,
from different tissues in large cohorts, and detailed models
that can be used for integrative analysis of such data. The diffi-
culties with identification of prognostic biomarkers solely using
plasma metabolomics are well illustrated by identification of sar-
cosine for prostate cancer progression (Sreekumar et al., 2009).
Later studies could not validate these findings (Jentzmik et al.,
2011; Ankerst et al., 2015), and like many other biomarkers it
has therefore not been translated for clinical use. Through the
combination of plasma metabolomics with other omics data, it
is possible to get a mechanistic explanation for changes in
metabolite levels. This has been demonstrated in several studies
where plasmametabolomics was used for genome-wide associ-
ation studies (GWASs). Using GWASs of more than 200 metab-
olites in a large cohort of more than 2,000 subjects with a
detailed cardiometabolic phenotyping resulted in identification
of inborn mutations in AGXT2, a transaminase, being associated
with altered cholesterol and triacylglycerol levels (Rhee et al.,
2013). In a later study on the same cohort, but using more
detailed genetic profiling, mutations in several metabolic en-
zymes were identified to be associated with altered plasma
metabolite levels (Rhee et al., 2016). GWAS analysis has also
been done with metabolome data from urine samples, and here-
by several loci were identified that have also earlier been identi-
fied to be important for clinical outcomes, and this led to the
identification of several potential metabolite biomarkers that
can be measured in urine (Suhre et al., 2011). These are exam-
ples of single genetic differences specifically causing an altered
enzyme activity, and they are valuable for identification of pa-
tients with increased risks for disease development, but GWASs
of plasma metabolome data do not allow for gaining insight into574 Cell Metabolism 25, March 7, 2017metabolic changes associated with disease onset that is not
caused by genetic dispositions.
Another challenge for systems medicine is that even though
there are many good model systems available for studying
different human diseases, the translation to the clinic often fails.
This is often ascribed to biological differences between, e.g.,
mouse and human, but it may equally well be due to impacts
of diet and lifestyle, as well as the presence of much larger var-
iations in genetics and gutmicrobiome composition between hu-
man individuals in a clinical trial than in a controlled preclinical
study. In the field of cancer, complexity is further added by a
large heterogeneity across and within tumors, which even ques-
tions the traditional histopathological classification of cancers.
N-of-1 trials on large cohorts will assist in overcoming some of
these challenges as it will allow the identification of the common-
alities across a population in connection with disease develop-
ment, i.e., which are truly conserved biomarkers and associated
mechanisms, and which are associated with specific genetic dif-
ferences and/or lifestyles. Such studieswill therefore assist in the
identification of prognostic biomarkers that can be used for strat-
ification and for prognosis of disease development.
The Central Role of Metabolism in Cellular Physiology
Metabolism plays a central role in living cells, for it provides the
energy and building blocks for cellular growth aswell as ensuring
protection against external stress factors, e.g., xenobiotics and
oxidative stress. Metabolism has evolved to support function
of the cell and can roughly be divided into three types: (1) central
carbon metabolism, which ensures conversion of carbon and
energy sources into free energy, redox power, and precursor
metabolites required for biosynthesis; (2) biosynthesis, where
precursors are converted into building blocks like amino acids,
nucleotides, fatty acids, etc. required for cell growth; and (3) sec-
ondary and endogenous metabolism, which is typically highly
diverse among cells. Enzymes of the central carbon metabolism
are the most catalytically efficient but have evolved to generally
be smaller than enzymes of other parts of metabolism (Bar-Even
et al., 2011). They are, however, still the most abundant in bacte-
ria, single-cell eukaryal cells like yeast, and human (Liebermeis-
ter et al., 2014). In microbes, about half of the proteome is allo-
cated to metabolism, with about 25% being allocated alone to
glycolysis, whereas in human this number is lower as a larger
fraction of the proteome is allocated to cytoskeleton proteins,
chaperones, and the spliceosome (Liebermeister et al., 2014).
The high catalytic efficiency, small size, and high abundance of
enzymes in the central carbon metabolism are consistent with
the central role this part of metabolism is playing in ensuring con-
stant provision of energy, primarily in the form of ATP, in handling
electron flows by balancing the co-factors NADH and NADPH,
and in providing precursors for cellular growth. Thus, the flux
through the central carbon metabolism typically exceeds the
flux through other metabolic pathways by a factor 10 or more.
With these multiple roles, the central carbon metabolism has to
be highly connected with the other parts of metabolism, i.e., in
yeast ATP is used in more than 200 out of about 1,500 metabolic
reactions, and metabolism therefore forms a highly connected
metabolic network (J.N., unpublished data). This means that a
perturbation of almost any part of metabolism results in a global
response in which a large number of enzymes have to alter their
AB C
Figure 2. Illustration of the Concept of Integrative Data Analysis Using Metabolic Networks
(A) Illustration of how a metabolic map, represented by a genome-scale metabolic model (GEM), can be used for integrative analysis of omics data, e.g.,
transcriptome, proteome, or metabolome data. By overlaying these data on themetabolic map, it is possible to identify reporter metabolites and/or sub-networks
that represent parts of metabolism that have altered activity in response to change, e.g., disease development. A set of reporter metabolites may be connected in
the metabolic network and thereby point to altered activity of non-canonical pathways.
(B) Illustration of how tissue-specific models are a subset of a generic GEM for human metabolism, here illustrated by HMR2.
(C) Example of a reporter sub-network identified in ccRCC using a specific cancer GEM together with transcriptome data from both the cancer tissue and
corresponding healthy kidney tissue. The sub-network involves a large number of reactions in heparan and chondroitin sulfate biosynthesis pointing to altered
levels of metabolism in plasma and urine.
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almost any perturbation of cellular physiology will have a meta-
bolic fingerprint, i.e., changes in a certain part of metabolism,
and this may be quite specific. It further means that with the
high degree of connectivity in metabolism, it is difficult to analyze
changes in metabolism without the use of mathematical models.
I therefore hypothesize that any disease onset will result in a shift
in the metabolic homeostasis in the body, and such shifts can
possibly be detected through metabolome analysis of plasma.
These changes may be very small, in particular at the early stage
of disease onset, and therefore difficult to detect unless a tar-
geted approach is applied. This has to follow a hypothesis gener-
ated from analysis of, e.g., transcriptome or proteome data from
tissues associated with the disease combined with integrative
analysis. As will be discussed below, GEMs represent an excel-
lent scaffold for this kind of analysis.Genome-scale Metabolic Models
Concept
GEMs are comprehensive compilations of all the metabolic reac-
tions that take place in a particular cell, tissue, organ, or organism
(O’Brien et al., 2015). Each reaction is associatedwith one ormore
enzymes and encoded by specific genes; thus, a direct gene-pro-
tein-reaction connection can be established. This is an important
feature of GEMs as it allows for overlaying omics-type data, e.g.,
transcriptome or proteome data, and thereby identifying co-regu-
lated sub-networks in metabolism (Figure 2A) (Patil and Nielsen,
2005). These co-regulated sub-networks, or reporter metabolites,
point to parts of the metabolism that need to have altered expres-
sion in order to maintain cellular homeostasis. Often these co-
regulated sub-networks are not directly associated with the parts
of metabolism that are affected (Patil and Nielsen, 2005). Thus, if
cells are exposed to oxidative stress there may be alterationsCell Metabolism 25, March 7, 2017 575
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coping with the oxidative stress, but also in more distant parts of
metabolism, e.g., the pentose phosphate pathway, ensuring
regeneration of NADPH used in glutathione metabolism.
Through specification of the stoichiometry of the different re-
actions in ametabolic network, GEMs can be used for simulation
of metabolic functions using the concept of flux balance analysis
(O’Brien et al., 2015). This concept assumes that all fluxes into
a metabolite pool equal all fluxes out of the pool. Of course,
perturbations of metabolism will result in deviations from this
steady-state condition, but the flux through most metabolite
pools is so high that the pool turnover is on the order of seconds
or minutes (depending on the part of metabolism), meaning
that a deviation from flux balancing will be resolved in just a
few seconds/minutes by the resulting rapid change in metabolite
levels. Flux balance analysis imposes a large number of
constraints on the fluxes and thereby allows for calculation of
fluxes through different parts of the metabolism based on mea-
surements of a few exchange fluxes, e.g., fluxes of nutrient up-
take, but as the degrees of freedom in these models is quite
large, all fluxes cannot be uniquely determined (Mardinoglu
and Nielsen, 2015). Recently it has, however, been shown that
by incorporating kinetic information into GEMs, together with a
constraint on proteome usage for metabolic enzymes, it is
possible to improve the predictive strength of GEMs significantly
(Thiele et al., 2012; Nilsson and Nielsen, 2016) and thereby
describe overflow metabolism to lactate in cancer cells (Shlomi
et al., 2011).
Human GEMs
In 2007, the two first GEMs for human metabolism were recon-
structed (Ma et al., 2007; Duarte et al., 2007), and these models
formed the basis for Recon2, a much expanded model with
broader coverage of metabolism (Thiele et al., 2013). In connec-
tion with building tissue-specific GEMs, more details in lipid
metabolism had to be incorporated and this resulted in Human
Metabolic Reaction (HMR2) (Agren et al., 2014), which is
currently the most comprehensive GEM for human cells,
covering 3,765 genes, 8,181 reactions, and 6,007 metabolites.
HMR2 has been used as a basis for reconstruction of detailed
models for different human cell types, which become sub-sets
of HMR2 (Figure 2B). Cell-type-specific GEMs have been recon-
structed for adipocytes (Mardinoglu et al., 2013), hepatocytes
(Mardinoglu et al., 2014b), and myocytes (V€aremo et al., 2015).
The adipocyte model was used for integrative analysis with the
objective of gaining insight into metabolic reprogramming in
abdominal fat tissues in response to obesity, and it was found
that respiratory metabolism was significantly reduced in obese
subjects. At the same time, catabolism of branched-chain amino
acids (valine, leucine, and isoleucine) was found to be attenuated
(Mardinoglu et al., 2014a), which can explain the elevated levels
of thesemetabolites in plasma (Newgard et al., 2009). The adipo-
cyte model was also used to illustrate that attenuated respiration
caused problems with oxidation of accumulated triacylglycerols
and therefore resulted in reduced dynamics of lipid bodies in
obese subjects (Mardinoglu et al., 2013). The myocyte model
was similarly used to identify co-regulated networks in meta-
bolism in response to type 2 diabetes (T2D), and for muscle tis-
sue attenuated catabolism of branched-chain amino acids was
identified (V€aremo et al., 2015), further pointing to a mechanistic576 Cell Metabolism 25, March 7, 2017basis for the elevated levels of these metabolites in plasma
in obese subjects or those with T2D. Other tissue-specific
GEMs have also been reconstructed computationally using
data from tissue-specific gene expression values (Shlomi et al.,
2008) or from data from the Human Protein Atlas (HPA) (www.
proteinatlas.org) (Agren et al., 2012, 2014). HPA data are partic-
ularly well suited for the generation of cell-type-specific GEMs,
for immunohistochemistry has been used for identifying the
presence of proteins in 80 different human cell types, and cell-
type-specific models can therefore be generated. These models
allow for direct analysis of the metabolism of different cell types
present in tissues, and thereby enable better understanding of
the mechanisms underlying changes in overall tissue meta-
bolism. RNA sequencing (RNA-seq) has recently been shown
to provide much new insight into biological differences between
different human tissues, and using this kind of data 32 tissue-
specific GEMs were generated (Uhle´n et al., 2015). Human
GEMs have also been used for the identification of novel
drug targets for cancer treatment (Folger et al., 2011), as thor-
oughly reviewed elsewhere (Yizhak et al., 2015), and recently
illustrated for argininosuccinate synthase (ASS1)-deficient tu-
mors (Rabinovich et al., 2015). These tumors have elevated
levels of aspartate, which is beneficial for de novo pyrimidine
biosynthesis, and it is therefore important to block this part of
metabolism in ASS1-deficient tumors. As mentioned above,
cancer cells are extremely heterogeneous, and using proteomics
data from hepatocellular carcinoma (HCC) tumors, personalized
GEMs were generated for six individuals with HCC (Agren et al.,
2014). HCCmetabolismwas indeed found to be quite different in
the six individuals, but by using theGEMs it was possible to iden-
tify anti-metabolites that block cell growth in all six tumors. One
of these targets was the carnitine carrier system, which is
responsible for the transport of fatty acids into the mitochondria
for b-oxidation and thereby ensures sufficient energy generation
for the cancer cells. Using HepG2 cells, a cell line derived from
HCC tumors, this target was validated and shown to prevent
cell proliferation (Agren et al., 2014). Considering the large het-
erogeneity in the six tumors, it is, however, very likely that this
identified drug target may not constitute an effective treatment
across larger cohorts, clearly pointing to the need for a more
personalized approach to cancer treatment. GEMs were also
used to contextualize gene expression changes independently
associated with distinct cancer mutations and revealed a trans-
versal metabolic signature revolving around arachidonic acid
and xenobiotic metabolism (Gatto et al., 2016a). This finding
may be important as it could lead to the identification of a treat-
ment strategy that can be used for several cancer types.
Identification of Metabolite Biomarkers
GEMs have in several cases demonstrated their power for iden-
tification of biomarkers that have subsequently been validated
from plasma metabolomics. Using a hepatocyte GEM, it was
possible to study metabolic reprogramming in response to
development of non-alcoholic fatty liver disease (NAFLD) (Mardi-
noglu et al., 2014b). From this analysis, it was found that patients
developing non-alcoholic steatohepatitis (NASH) had a signifi-
cant decreased expression of genes encoding for enzymes in
serine and glycine biosynthesis, which can explain observation
of elevated levels of plasma homocysteine (Gulsen et al., 2005)
and decreased levels of phosphatidylserine in the liver of
Cell Metabolism
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a follow-up study in which it was shown that NASH patients have
reduced levels of serine and glycine in the plasma, pointing to
serine deficiency in these patients (Mardinoglu et al., 2016).
Moreover, serine supplementation could improve the health sta-
tus of such patients. This study gives a very strong indication that
serine and glycine levels in plasma can be used as a non-invasive
biomarker for NASH development in patients with a fatty liver.
HMR2 has also been used to find a very strong prognostic
biomarker for clear cell renal cell carcinoma (ccRCC). This was
identified from a study that initially evaluated metabolic reprog-
ramming in eight different cancers using RNA-seq data from
the Cancer Genome Atlas (TGCA) database (Gatto et al.,
2014). From this analysis, ccRCC was found to have a unique
metabolic reprograming, distinctive from the other epithelial can-
cers. This was, in turn, associated with repression of metabolic
functions in several different parts of metabolism, e.g., nucleo-
tide metabolism, which makes the tumor more vulnerable
against inhibition of specific enzymatic functions according to
experimentally validated GEM-based simulations (Gatto et al.,
2015). More importantly, the integrative data analysis also iden-
tified a strong de-regulation of heparan and chondroitin sulfate
biosynthesis, and subsequent quantification of these metabo-
lites in the plasma and urine of patients with metastatic ccRCC
resulted in identification of a systems biomarker that is deter-
mined by altered levels of several of these metabolites (Gatto
et al., 2016b). This systems biomarker was further found to
have prognostic value; it can predict the aggressiveness of the
tumor and thereby survival rate of ccRCC patients (Gatto et al.,
2016c), and it is now being brought to the clinic for evaluation
of its diagnostic and predictive capabilities for the treatment
of ccRCC.
Finally, a recent study used HMR2 in combination with a bio-
logical network derived from protein-protein interactions for
analysis of transcriptome and proteome data for insulin-resistant
patients and matched controls (Lee et al., 2016). This resulted in
the identification of mannose metabolism to be significantly
altered in insulin-resistant patients, and subsequent analysis of
metabolomics from more than 1,000 subjects could validate
mannose as a novel biomarker for insulin resistance (Lee
et al., 2016).
The above-mentioned studies are all examples of how sys-
tems biology analysis of specific human tissues resulted in the
identification of changes in specific parts of the metabolic
network, and these changes resulted in altered plasma metabo-
lite levels. It would have been difficult to identify these bio-
markers without a directed search, but based on identified and
statistically significant alterations in the metabolic networks, a
hypothesis could be generated about certain metabolites being
likely biomarkers, and from targeted metabolomics these could
thereafter be validated. The strength of this approach is that
not only are novel biomarkers identified, but a mechanistic
explanation for their function is directly provided.
Perspectives
There are some challenges for advancing systems medicine,
but these basically condense into developing better methods
for integrative analysis of data and the establishment of N-of-1
clinical trials with large cohorts. Even though there are severalongoing and planned N-of-1 clinical trials, it is important to
further expand and include more subjects and also expand the
scope of some of these studies to ensure that very detailed
phenotypic characterization of the individuals is performed. As
discussed, GEMs offer much in terms of integrative analysis,
and through further expansion of the models with description
of protein synthesis and other cellular processes, the scope of
these models will expand and allow for simulating the impact
of many key cellular processes underlying human diseases,
e.g., oxidative stress and protein mis-folding stress. Other
computational approaches should, however, also be consid-
ered. Recent development in machine learning, with emphasis
on deep learning (Angermueller et al., 2016), has shown to be
powerful for analyzing large datasets and holds promise to adapt
to problems in computational biology that may in the future
assist with diagnostics in the clinic. This was excellently illus-
trated in a large dietary N-of-1 clinical study that was carried
out with the objective of enabling personalized dietary advice
(Zeevi et al., 2015). Using a very large dataset, involving an
800-person cohort with measured responses to more than
45,000 meals, a machine-learning algorithm was generated by
integrating blood chemistry, dietary habits, and gut microbiota
composition. Using the algorithm, it was possible to successfully
predict glycemic responses in a 100-person follow-up cohort,
demonstrating that this algorithm can be used for personalized
nutritional advice. Even though machine-learning algorithms
cannot directly providemechanistic insight, these algorithms still
allow for providing clear connectivity between a very large num-
ber of variables, and these can then be used for follow-up studies
with the objective of identifying the underlying mechanisms.
The above-mentioned study, likemany otherN-of-1 clinical tri-
als, included analysis of the gut microbiota, as this has been
shown to have a large impact on overall human metabolism
(Karlsson et al., 2013a; Arora and B€ackhed, 2016; Wu et al.,
2015). However, even though clear correlations have been iden-
tified between the gut microbiota and many different human dis-
eases, e.g., T2D (Karlsson et al., 2013b), most of these studies
are only correlative and no causal effects have been identified.
Here mathematical modeling can assist in gaining insight into
the interaction between the many different species and their
host (Heinken and Thiele, 2015). The gut microbiota represents
a very complex ecosystem with a large number of species that
express different metabolic phenotypes. GEMs are well suited
for modeling of this kind of ecosystem:models for individual spe-
cies can capture the overall metabolism of each species, and
various algorithms can then be used for simulation of their inter-
actions (Shoaie et al., 2013). Hereby it has been demonstrated
that it is possible to simulate how the human gut microbiota is
impacted by diet and how it impacts plasma chemistry, including
the level of many amino acids (Shoaie et al., 2015). Even though
this last study only considered the five most dominant species in
the gut microbiota, it clearly demonstrates that it is becoming
possible to simulate how this complex ecosystem is impacted
by diet and how it interacts with host metabolism. By adding
more models, it will become possible to simulate not only the
impact of diet on the gut microbiome development but also
how the gut microbiome should be modulated, e.g., through
addition of new probiotics, in order to attain properties associ-
ated with healthy subjects. Here a recent study describing 773Cell Metabolism 25, March 7, 2017 577
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PerspectiveGEMs for gut symbionts provides a valuable resource for ex-
panding our description of the gut microbiota metabolism
(Magnu´sdo´ttir et al., 2017). Hereby it may also become possible
to use probiotics as combination treatment with drugs that are
impacted by the gut microbiota composition, as identified for
some anti-cancer drugs (Ve´tizou et al., 2015; Sivan et al., 2015).
From the above, it is clear that systems biology can lead to
identification of novel biomarkers and drug targets, and at the
same time provide a mechanistic explanation for why they can
be used for diagnosis and in development of effective treatment
strategies. However, much more data are needed in order to
develop strong biomarkers that are personalized and allow for
precise detection of disease onset. GEMs represent an excellent
scaffold for analysis of this kind of data, and a particular strength
of thesemodels is that they are open ended in the sense that they
can be expanded with more biological knowledge and thereby
acquire increasing predictive strength. I am therefore confident
that together with big data obtained from large N-of-1 clinical
studies, GEMs will contribute significantly to the advancement
of personalized and precision medicine in the next 5–10 years.ACKNOWLEDGMENTS
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